Enter Your Email Address to Receive a
Copy of MedicExhange Member Demograhpics

Siemens PETNET Solutions announced the expansion of its imaging biomarker production capabilities in Nottingham, England

Siemens PETNET Solutions; A Division of Siemens PLC, announced the expansion of its imaging biomarker production capabilities in Nottingham, England to include the ability to produce new biomarkers as investigational medicine products (IMP) in the United Kingdom. These IMPs include a proprietary hypoxic agent developed by Siemens for identification of tumor tissues with low oxygen supply, and a leading investigational amyloid agent, for PET imaging of β-amyloid deposits in the brain.

PETNET Solutions’ recent and significant investments to build radiopharmaceutical manufacturing and distribution capabilities in areas, such as the UK, support its own global growth strategy, as well as the commercialization of new imaging agents. Siemens and third-party evaluations for new drugs or treatments can be facilitated by the worldwide manufacturing and distribution of radiopharmaceuticals from PETNET solutions.

PETNET Solutions operates the largest network of PET radiopharmaceutical production facilities with 54 production and distribution centers worldwide.

Source: Siemens Healthcare

Click on the link to see more PET Companies